Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

One dose vaccination with mycoplasma hyopneumoniae

A Mycoplasma hyopneumoniae and vaccine technology, applied in the direction of vaccines, veterinary vaccines, DNA/RNA vaccination, etc., to achieve the effect of treating or preventing symptoms, preventing and alleviating lesions

Inactive Publication Date: 2004-12-01
ZOETIS SERVICE LLC
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] None of the known M. hyopneumoniae vaccines have been reported to be effective when given as a single dose in pigs of approximately 3-10 days of age

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Preparation of Mycoplasma Hyopneumoniae Vaccine

[0075] Mycoplasma hyopneumoniae NL1042 strain was inactivated with binary ethyleneimine (BEI).

[0076] At the end of the growth period, the pH of the culture was adjusted to 7.8 ± 0.2 and kept within this range for at least one hour. During this period, filter-sterilized 2-BromoEthylAminehydrobromide (BEA) aqueous solution was added to a final concentration of about 4.0 mM. At elevated pH, BEA is chemically converted to BEI. The cultures were incubated at 37±2°C for at least 24 hours with constant agitation.

[0077] After 24 hours of incubation, filter-sterilized aqueous sodium thiosulfate solution was added to a final concentration of about 4 mM to neutralize excess BEI. The culture was then incubated for 24 hours at 37±2°C with continuous agitation.

[0078] After inactivation, but before neutralization with sodium thiosulfate, samples were taken and tested for inactivation completion. New medium...

Embodiment 2

[0087] animal

[0088] Pigs of approximately 1 week of age were selected for vaccination. The serum status of Mycoplasma hyopneumoniae was determined by ELISA experiment. Pigs with an ELISA value ≤ 0.50 were negative for Mycoplasma hyopneumoniae. Pigs with an ELISA value greater than 0.50 were seropositive for Mycoplasma hyopneumoniae.

[0089] vaccine

[0090] M. hyopneumoniae bacterin RESPISURE-1 (Pfizer) was used to immunize pigs. Before using the vaccine, its potency is determined by the relative antigen content compared with the reference Mycoplasma hyopneumoniae bacterin. The reference vaccine (RP=1.0) contained approximately 8000 units of antigen per dose (approximately 1-2 x 10 8 CCU), it is detected by the solid-phase immunoassay capable of measuring the Mycoplasma hyopneumoniae antigen in the vaccine.

[0091] The same liquid adjuvant (AMPHIGEN) used in the preparation of RESPISURE-1 was used as placebo (ie, without bacterial cells.)

[0092] challenge in...

Embodiment 3

[0104] Protection against virulent M. hyopneumoniae challenge in pigs, M. hyopneumoniae seropositive pigs administered a single dose of the M. hyopneumoniae vaccine RESPISURE-1 (Pfizer) at 3-8 days of age was evaluated.

[0105] Five replicate titer assays were performed on RESPISURE-1 at or before vaccination. Relative potency (RP) was determined using the relative amount of antigen compared to the vaccine reference. The vaccine reference had RP = 1.0 and contained about 8000 units of M. hyopneumoniae antigen. The RP values ​​of the five experiments were 5.42, 3.96, 4.71, 5.49 and 4.36, respectively.

[0106] On day 0, pigs in the T02 treatment group (see Table 1 below) were inoculated intramuscularly with M. hyopneumoniae bacterin RESPISURE-1 (Pfizer) at a dose of 2 ml. Pigs in the T01 group were inoculated intramuscularly with a dose of 2 ml of placebo. On days 178, 179 and 180, each pig was inoculated nasally with a dose of 5 ml of a 1:25 challenge inoculum suspension. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

Description

field of invention [0001] The present invention relates to a method for treating or preventing animal diseases or conditions caused by Mycoplasma hyopneumoniae infection by administering a single effective dose of Mycoplasma hyopneumoniae (M.hyo) vaccine to animals about 3 to 10 days old . The Mycoplasma hyopneumoniae vaccine may be completely or partially inactivated cells or modified living preparations, subunit vaccines, or nucleic acid or DNA vaccines. M. hyopneumoniae vaccines administered in accordance with the present invention may be prepared synthetically or recombinantly. Background of the invention [0002] Mycoplasma hyopneumoniae (M.hyo) is a bacterial pathogen that can cause enzootic pneumonia in swine. Enzootic pneumonia is a chronic disease resulting in poor food conversion, developmental impairment, and susceptibility to secondary pulmonary infection. M. hyopneumoniae is easily transmitted through respiratory secretions and through ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61DA61K39/02A61K39/116A61K39/12A61K39/145A61K39/295A61K39/395A61P31/00A61P31/04A61P43/00
CPCA61K2039/55555Y10S435/87A61K2039/545A61K2039/521A61K39/0241A61K2039/552A61K2039/53A61P31/00A61P31/04A61P43/00A61K39/02
Inventor R·L·凯赫L·G·萨巴迪尼
Owner ZOETIS SERVICE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com